ArticleFrontiers in bioinformatics2026
An explainable-AI framework reveals novel lncRNAs specific for breast cancer subtypes.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Long non-coding RNAs (lncRNAs) have emerged as important regulators in cancer biology; yet their potential for cancer subtyping remains underexplored particularly in the context of large-scale, multi-class supervised classification frameworks, due to limited publicly available data or their use only as auxiliary features in classification tasks. Methods: In this study, we utilized an expansive set of 7,177 lncRNAs obtained from 1,021 breast cancer (BRCA) transcriptomics datasets for subtyping using an explainable artificial intelligence (AI) framework. lncRNA, mRNA, and miRNA features were used to build machine learning (ML) models individually and in combination. Four ML classifiers: Naïve Bayes, Random Forest, Artificial Neural Network, and XGBoost were employed to evaluate subtype classification performance. Results: Using lncRNAs alone, XGBoost demonstrated strong performance with an accuracy of 89.2% and AUROC of 0.99. Addition of miRNA or mRNA features to lncRNA marginally improved the accuracy to 90.8% and 92.2%, respectively, while using all the three features together provided no further gain. A sequential key feature identification pipeline (ANOVA, Boruta, SHAP) has identified interpretable subtype-specific biomarker panels, yielding 119, 66, 54, and 24 unique features for Luminal A, Luminal B, HER2+, and Basal subtypes, respectively. Further lncRNA characterization followed by survival analysis revealed significant subtype-specific novel lncRNAs, including CUFF.25255 (LumA), CUFF.20237 and CUFF.3888 (LumB), CUFF.22414 (HER2+), and CUFF.26607 and CUFF.1961 (Basal). Conclusion: Our findings highlight the diagnostic and biomarker discovery potential of lncRNAs, and the explainable-AI framework implemented here provides a systematic large-scale evaluation of lncRNA-only and integrative models for multi-class BRCA subtyping for BRCA subtyping and can be adopted to other cancers using the existing cancer transcriptomics data in the public databases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.